TRV-2026-1229Version 2 · Revised

Saved · see the current record

Why this version exists

Direction audit: the gain line stated no AI consequence and was removed. Filed as context; not counted as a gain or a problem.

The exact text we saved

This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.

TRUVACE RECORD VERSION
record: TRV-2026-1229
version: 2
kind: revised
reason: Direction audit: the gain line stated no AI consequence and was removed. Filed as context; not counted as a gain or a problem.
timestamp: 2026-10-26T06:38:38.206714Z
status: published
lens: general
sector: health
headline: Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI
dek: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational...
gain_title: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.
problem_title: (none)
trace_subject: (none)
gain_reading: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.
gain_evidence: design and optimize novel enzyme therapies for BioMarin's pipeline | Profluent announced a collaboration with BioMarin Pharmaceutical Inc.
problem_reading: (none)
problem_evidence: (none)
quick_read: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline, with Profluent applying its foundational technology under the agreement.

The partnership illustrates use of AI-driven protein design in pharmaceutical development, but the supplied text does not detail specific targets, timelines, performance results, or clinical outcomes, leaving efficacy and translational impact uncertain.
limitation: 
tag: Context
key_points: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. | The stated goal is to design and optimize novel enzyme therapies for BioMarin's pipeline. | Under the agreement Profluent will apply its foundational AI technology to the effort.
rundown: On September 30, 2026, Profluent announced a collaboration with BioMarin Pharmaceutical Inc. focused on novel enzyme therapies.

The agreement positions Profluent to apply its foundational platform to design and optimization work intended to support BioMarin's pipeline.
sources:
- journalism | MarketScreener | https://www.marketscreener.com/news/profluent-and-biomarin-pharmaceutical-inc-partner-to-design-novel-medicines-using-ai-ce785ad3d88bf623 | 2026-09-30
prev: 8507a350b89fd66b3a9cca5d7d2fc9cf31c7704f64c688898ed83b06a23bf708
SHA-256 hash
bc4a4ead1d7a34684900415e70709ed08b552759b3815873f44e9be914b8bf75
Previous version’s hash
8507a350b89fd66b3a9cca5d7d2fc9cf31c7704f64c688898ed83b06a23bf708
Check this record hasn’t been altered
How to check it yourself, without trusting this page

Download any version from /api/record/TRV-2026-1229 and hash its canonical field yourself, for example with shasum -a 256. You should get its content_hash. Each version’s text also ends with prev:and the hash of the version before it (version 1 points to 64 zeros). If anyone had changed a single character of any version after it was saved, those hashes wouldn’t line up.